Abstract
Objective: To investigate the serum expression of Glycosylphosphatidylinositol Mannosyltransferase 1 (GMP1) in type 2 diabetes mellitus (T2DM) patients and its correlation with hypertriglyceridemia (HTG) to shed light on lipid metabolism disorders in T2DM.
Methods: A total of 239 subjects were included, among whom 92 patients were in the T2DM combined with HTG group and 147 patients were in the T2DM without HTG group. The concentration of the serum GMP1 protein was quantitatively detected via enzyme-linked immunosorbent assay (ELISA). Moreover, the levels of serum triglycerides (TGs) and other related metabolic indicators (such as blood glucose, glycated hemoglobin (HbA1c), total cholesterol, and high/low-density lipoprotein cholesterol) were detected via conventional biochemical methods. To evaluate the potential impact of GMP1 on the occurrence of T2DM combined with HTG.
Results: Both the DM group and the DM+HTG group had significantly higher serum GMP1 levels (P<0.01), and the GMP1 level in the DM+HTG group was considerably higher (P<0.05 or 0.01) than in the simple DM group. The serum GMP1 levels in T2DM and HTG patients were significantly higher. Serum GMP1 level (OR=1.527, 95% CI 1.200--1.943) were all determined by binary logistic regression analysis. 95% CI 1.003–1.010) was a separate risk factor for HTG and T2DM. Correlation analysis revealed that in patients with T2DM (especially those in the DM+HTG group). Multiple regression analysis further indicated that after controlling for factors such as age, sex, disease duration, BMI, and HbA1c, Higher blood GMP1 levels continued to be a predictor or independent factor for patients with T2DM complicated by HTG (P<0.05).
Conclusion: Serum GMP1 levels are markedly elevated in T2DM patients, especially those with hypertriglyceridemia, and they are independently positively linked with triglycerides.
Keywords
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.